Table 1.
Absolute and relative frequencies of characteristics of young mothers and OVIS participants with breast cancer (BC)
| Young mothers with BC |
Women with BC from OVIS study | ||||
|---|---|---|---|---|---|
| total | < 36 years | 36–39 years | ≥ 40 years | ||
| Women, n | 1,191 | 266 | 320 | 605 | 1,879 |
| Time period of diagnosis | 2006–2014 | 2001–2004 | |||
| Age at diagnosis, mean + SD | 39.6 + 5.5 | 32.1 + 2.51 | 37.5 + 1.14 | 44.1 + 3.04 | 58.8 + 11.3 |
| (range), years | (21–54) | (21–35) | (36–39) | (40–54) | (25–85) |
| Age group, n (%) | |||||
| <36 years | 266 (22.3) | n.a. | n.a. | n.a. | 32 (1.7) |
| 36–39 years | 320 (26.9) | 70 (3.7) | |||
| ≥40 years | 605 (50.8) | 1,777 (94.6) | |||
| Menopausal status, n (%) | |||||
| Pre | 180 (16.1) | 51 (20.6) | 51 (16.8) | 78 (13.7) | n.a. |
| Peri | 143 (12.8) | 51 (20.6) | 49 (16.1) | 43 (7.6) | |
| Post | 798 (71.2) | 146 (58.9) | 204 (67.1) | 448 (78.7) | |
| Missing | 70 | 18 | 16 | 36 | |
| Civil status, n (%) | |||||
| Single | 185 (15.6) | 48 (18.2) | 51 (16.1) | 86 (14.3) | 118 (6.3) |
| Married | 832 (70.3) | 200 (75.8) | 223 (70.6) | 409 (67.8) | 1,234 (66.0) |
| Divorced | 150 (12.7) | 16 (6.1) | 41 (13.0) | 93 (15.4) | 191 (10.2) |
| Widowed | 16 (1.4) | - | 1 (0.3) | 15 (2.5) | 328 (17.5) |
| Missing | 8 | 2 | 4 | 2 | 8 |
| Tumor size, n (%) | |||||
| T0 | 85 (7.2) | 32 (12.2) | 26 (8.2) | 27 (4.5) | - |
| T1 | 591 (50.1) | 126 (47.9) | 161 (50.9) | 304 (50.6) | 1,043 (56.2) |
| T2 | 434 (36.8) | 87 (33.1) | 111 (35.1) | 236 (39.3) | 667 (36.0) |
| T3 | 62 (5.3) | 16 (6.1) | 17 (5.4) | 29 (4.8) | 87 (4.7) |
| T4 | 8 (0.7) | 2 (0.8) | 1 (0.3) | 5 (0.8) | 58 (3.1) |
| Tx | 11 | 3 | 4 | 4 | 22 |
| Axillary lymph node status, n (%) | |||||
| N0 | 682 (57.9) | 155 (59.2) | 187 (59.4) | 340 (56.7) | 1,184 (65.2) |
| N1 | 337 (28.6) | 77 (29.4) | 82 (26.0) | 178 (29.7) | 568 (31.3) |
| N2 | 108 (9.2) | 18 (6.9) | 32 (10.2) | 58 (9.7) | 60 (3.3) |
| N3 | 50 (4.2) | 12 (4.6) | 14 (4.4) | 24 (4.0) | 5 (0.3) |
| Nx | 14 | 4 | 5 | 5 | 62 |
| Grading, n (%) | |||||
| G1 | 71 (6.2) | 7 (2.7) | 17 (5.6) | 47 (8.1) | 208 (11.5) |
| G2 | 529 (46.3) | 91 (35.7) | 127 (41.5) | 311 (53.5) | 1,065 (58.9) |
| G3 | 542 (47.5) | 157 (61.6) | 162 (52.9) | 223 (38.4) | 536 (29.8) |
| Gx | 49 | 11 | 14 | 24 | 70 |
| Receptor status, n (%) | |||||
| ER-positive | 833 (70.4) | 142 (53.8) | 209 (65.5) | 482 (80.2) | n.a. |
| Missing | 7 | 1 | 1 | 4 | |
| PR-positive | 747 (63.1) | 128 (48.3) | 182 (56.9) | 437 (73.0) | |
| Missing | 8 | 1 | 1 | 6 | |
| HER2/neu-positive | 282 (24.1) | 75 (29.0) | 90 (28.5) | 117 (19.7) | |
| Missing | 23 | 7 | 4 | 12 | |
| Triple-negative | 243 (20.6) | 89 (33.8) | 70 (21.9) | 84 (14.0) | |
| Missing | 10 | 3 | 1 | 6 | |
SD = Standard deviation; n.a. = not available; ER = estrogen receptor; PR = progesterone receptor.